The Haystack Project urges the OIG to develop a safe harbor to enable financial assistance from charitable entities, and directly from a manufacturer, so that patients can access the rare disease treatment they need.
Recordati Rare Drug's comment letter urges adjustments to the methodology used to calculate and recalibrate Medicare Severity Diagnosis-Related Groups.
Agilis' comment letter on IPPS urges equitable payment for rare diseases.
Read comments from the National MPS Society on IPPS urging making access to treatment for patients with rare diseases a priority.
Read the Bellicum Pharmaceuticals comment on the Hospital Inpatient proposed rule.